Chronic Lymphocytic Leukemia News
Patients with CLL who have complex karyotype appear to have better clinical outcomes with venetoclax and obinutuzumab compared with chlorambucil and obinutuzumab.
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
Median progression-free survival was 34.2 months in patients who received ofatumumab and 16.9 months in patients who received no additional treatment.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
The analysis revealed that Medicare beneficiaries had different treatment outcomes compared with the trial participants.
Addressing increased adverse events could be unmet medical need for Medicare-aged patients.
More than half of the patients with CLL included in the retrospective study first received a novel agent in the second-line setting.
There is an increasing focus on using the achievement of undetectable MRD in bone marrow as a clinical trial end point in patients with CLL.
An earlier study of obinutuzumab + venetoclax in combination with ibrutinib in patients with CLL showed high rates of diarrhea, bruising, and infusion-related reactions.
A third-generation anti-CD19 CAR-T cell therapy showed no major safety concerns and early signs of clinical activity for patients with lymphoid malignancies.
The FDA has approved Calquence (acalabrutinib; AstraZeneca) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
Patients receiving ibrutinib for chronic lymphocytic leukemia experienced an average weight gain of 2.4 kg at 1 year after therapy initiation.
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
The risk may be transient, as immune function recovered in late phases of treatment.
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
The risk for second primary malignancy appeared to increase over time in survivors of chronic lymphocytic leukemia compared with the general population.